Condition
    Moderate Evidence
    Effectiveness 4/5

    Myo-Inositol for PCOS (Polycystic Ovary Syndrome)

    4 g myo-inositol daily (ideally with 100 mg d-chiro-inositol in the 40:1 ratio) is a legitimate first-line option in PCOS.

    Overview

    Myo-inositol is the best-evidenced supplement for polycystic ovary syndrome, and the reason is that it targets the mechanism most PCOS phenotypes share: impaired insulin signalling. Randomised trials consistently show improved insulin sensitivity, lower fasting insulin and modest improvements in ovulation rate and menstrual regularity over three to six months. The caveat that a careful reader should hold on to is certainty. A Cochrane review of inositol for subfertile women with PCOS rated the evidence as very low quality, and although pooled analyses report more ovulatory cycles and better metabolic markers, live-birth data remain inconclusive. The metabolic story is stronger than the fertility story. Expect a hormonal and cycle effect measured in months, not weeks, and expect it to work alongside weight, sleep and activity changes rather than in place of them.

    Verdict

    Strong yes

    Multiple meta-analyses show improved insulin sensitivity and more ovulatory cycles at 2-4 g daily over 3-6 months. Trials are small and heterogeneous, and live-birth evidence is still weak.

    How It Works

    Inositols are the backbone of inositol phosphoglycan second messengers, which sit downstream of the insulin receptor. Myo-inositol mediates glucose uptake; D-chiro-inositol mediates glycogen synthesis and androgen production in the ovary. In PCOS, the enzyme epimerase that converts myo- to D-chiro-inositol appears to be over-active in the ovary, so the follicular fluid ends up myo-inositol depleted, and FSH signalling in the granulosa cell is impaired. Supplying myo-inositol restores that ratio, improves the FSH response, and lowers circulating insulin. Because insulin drives ovarian androgen output and suppresses hepatic sex hormone binding globulin, less insulin means less free testosterone, which is the route by which cycles become more regular and hirsutism slowly improves. This is also why the 40:1 myo- to D-chiro-inositol ratio is used: it approximates the physiological plasma ratio, and D-chiro-heavy formulas have been associated with worse oocyte quality at high doses.

    Pathways involved

    Inositol phosphoglycan insulin second messengers
    Restored myo- to D-chiro-inositol ratio in follicular fluid
    Improved granulosa cell FSH signalling
    Lower fasting insulin and HOMA-IR
    Reduced ovarian androgen production
    Higher sex hormone binding globulin

    Dosing & Protocol

    Dosing used in trials

    ScenarioDoseFormTiming
    Standard PCOS protocol4 g dailyMyo-inositol powder or capsules2 g twice daily with food
    Combination formula2 g myo-inositol + 50 mg D-chiro-inositol40:1 ratioTwice daily
    Metabolic markers only2 g dailyMyo-inositolOnce or twice daily
    Often added alongside200-400 mcg folic acidAs used in most trial armsDaily

    Trials ran 12 to 24 weeks. Doses above 4 g daily have not shown extra benefit and increase gastrointestinal upset.

    A six-month trial

    1. 1

      Get baseline numbers· Week 0

      Fasting insulin and glucose, HbA1c, total and free testosterone, SHBG, LH and FSH, plus a record of your cycle length over the last three months.

    2. 2

      Start at 2 g daily· Week 1

      One 2 g dose with food for a week to check gastrointestinal tolerance.

    3. 3

      Move to 4 g in split doses· Weeks 2-24

      2 g twice daily, ideally a 40:1 myo- to D-chiro-inositol product.

    4. 4

      Track cycles, not symptoms· Months 2-4

      The first measurable signal is usually cycle length shortening toward 35 days or less, and returning ovulation confirmed by luteal progesterone or ovulation tests.

    5. 5

      Reassess at 6 months

      Repeat insulin and androgen labs. No change in cycles or metabolic markers by month six is a fair non-response.

    6. 6

      Keep the basics running· Ongoing

      A 5-10% weight reduction where relevant, resistance training and sleep regularity all improve insulin sensitivity more than any supplement does.

    Metformin is still the comparator

    Head-to-head trials suggest myo-inositol achieves similar metabolic improvements to metformin with fewer gastrointestinal side effects, but metformin has far larger and longer outcome data. If you are already on metformin, myo-inositol is an addition to discuss, not a replacement to make on your own.

    Evidence

    Three pooled analyses anchor the metabolic claim. A 2017 meta-analysis of randomised trials in Endocrine Connections reported significant reductions in fasting insulin and HOMA-IR and improvements in testosterone and SHBG at 2 to 4 g daily. A 2018 meta-analysis in BJOG found higher ovulation and clinical pregnancy rates for inositol treatment of anovulation, and an older BMJ network analysis of insulin-sensitising agents placed inositols in the same broad space as metformin for ovulation induction. Against that, the 2018 Cochrane review of inositol in subfertile women with PCOS graded the evidence very low quality and could not confirm an effect on live birth or clinical pregnancy. The trials are small, dosing and formulations differ, and several were industry supported. The defensible reading: reliable improvements in insulin sensitivity and cycle regularity, probable improvement in ovulation, unproven effect on live births.

    Pooled analyses and trials linked to this pairing, newest first.

    Ovulation induction with myo-inositol alone and in combination with clomiphene citrate in polycystic ovarian syndrome patients

    Score: 5/10
    2007

    Papaleo E, Unfer V, Baillargeon JP +7 more

    Myo-inositol alone and with clomiphene citrate restored ovulation in polycystic ovary syndrome patients.

    View source

    Inositol treatment of anovulation in women with polycystic ovary syndrome: a meta-analysis of randomised trials

    Score: 8/10
    2018
    meta_analysis

    Pundir J, Psaroudakis D, Savnur P +5 more

    Inositol improved ovulation rate and cycle frequency versus placebo and produced metabolic improvements comparable to metformin.

    View source

    Experts' opinion on inositols in treating polycystic ovary syndrome and non-insulin dependent diabetes mellitus: a further help for human reproduction and beyond

    Score: 5/10
    2015
    systematic_review

    Facchinetti F, Bizzarri M, Benvenga S +13 more

    The 40:1 myo-inositol to D-chiro-inositol ratio is recommended for restoring ovulation and insulin sensitivity.

    View source

    Myo-inositol effects in women with PCOS: a meta-analysis of randomized controlled trials

    Score: 7/10
    2017
    meta_analysis

    Unfer V, Facchinetti F, Orru B +2 more

    Myo-inositol supplementation significantly reduced fasting insulin and HOMA index and improved androgen profiles in women with PCOS.

    View source

    Inositol for subfertile women with polycystic ovary syndrome

    Score: 9/10
    2018
    meta_analysis

    Showell MG, Mackenzie-Proctor R, Jordan V +2 more

    It remains uncertain whether inositol improves live birth or clinical pregnancy rates, although there was some evidence of improved ovulation.

    View source

    What the numbers look like

    Typical effect on fasting insulin
    Meaningful reduction in HOMA-IR across pooled trials
    Ovulation
    Higher ovulatory rate than placebo in most trials
    Live birth
    Not established; Cochrane rated evidence very low quality
    Time to signal
    3-6 months for cycle and metabolic change

    Safety

    PCOS needs a diagnosis, not a guess

    Irregular cycles and raised androgens also occur in thyroid disease, hyperprolactinaemia, non-classical congenital adrenal hyperplasia and Cushing syndrome. Cycles longer than 90 days, virilisation, galactorrhoea or rapid symptom onset all need assessment before you treat yourself for PCOS.

    Reported side effects

    Nausea at doses above 4 g daily
    Loose stools
    Bloating
    Headache (uncommon)
    Dizziness (uncommon)
    Myo-inositol has a benign safety profile at trial doses; it is a naturally occurring compound with an estimated dietary intake of about 1 g daily from fruit, beans and grains. Adverse events in trials were mild and mostly gastrointestinal above 4 g. Two situations deserve care. If you are trying to conceive, restoring ovulation means fertility may return quickly, which matters for contraception decisions either way. And if you are also taking glucose-lowering medication, improved insulin sensitivity can add to that effect, so monitor for hypoglycaemia symptoms in the first few weeks.

    Interactions & Conflicts

    Interactions worth knowing

    Interacts withSeverityMechanismAction
    Metformin
    low
    		Additive improvement in insulin sensitivityCommonly combined, but tell your prescriber and watch for low blood sugar
    Insulin or sulfonylureas
    moderate
    		Additive glucose loweringMonitor glucose; dose adjustment may be needed
    Ovulation induction agents (clomiphene, letrozole)
    low
    		Inositol may improve response, raising multiple-follicle riskOnly alongside fertility monitoring
    High-dose D-chiro-inositol products
    moderate
    		Excess D-chiro-inositol has been linked to poorer oocyte qualityStay with a 40:1 myo- to D-chiro-inositol ratio
    Lithium
    low
    		Lithium acts partly by depleting inositol signallingDiscuss before starting; theoretical reduction in effect

    References

    1. Pundir J et al. Inositol treatment of anovulation in women with polycystic ovary syndrome: a meta-analysis of randomised trials. BJOG, 2018.DOI: 10.1111/1471-0528.14754
    2. Showell MG et al. Inositol for subfertile women with polycystic ovary syndrome. Cochrane Database Syst Rev, 2018.DOI: 10.1002/14651858.CD012378.pub2
    3. Unfer V et al. Myo-inositol effects in women with PCOS: a meta-analysis of randomized controlled trials. Endocr Connect, 2017.DOI: 10.1530/EC-17-0243
    4. Facchinetti F et al. Experts opinion on inositols in treating polycystic ovary syndrome and non-insulin dependent diabetes mellitus. Expert Opin Drug Metab Toxicol, 2015.DOI: 10.1517/17425255.2015.1128888
    5. Misso ML et al. Insulin-sensitising drugs for ovulation induction in polycystic ovary syndrome. BMJ, 2012.DOI: 10.1136/bmj.d6556
    6. Gerli S et al. Ovulation induction with myo-inositol alone and in combination with clomiphene citrate. Gynecol Endocrinol, 2007.DOI: 10.1080/09513590701672405

    Frequently Asked Questions

    Medical Disclaimer

    The information provided on this website is for educational and informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or before starting any supplement regimen.

    Individual results may vary. The statements on this website have not been evaluated by the Food and Drug Administration. Products and information are not intended to diagnose, treat, cure, or prevent any disease.